facebook pixel

About Catalyst

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases.

Our mission

To improve the lives of patients with rare and ultra-rare diseases
At Catalyst, we utilize leading-edge science in search of therapies that will improve the lives of those who suffer from rare-diseases, often without any therapeutic options. We believe that no other field of medicine holds as much promise and makes such a significant impact on patients’ lives as the development of novel orphan drugs.

Our values

At Catalyst, our three core values are: Passion, Trust, and Integrity. We strive to maintain these ideals both personally and professionally.

  • Passion is our commitment to engage, energize and inspire others and ourselves
  • Trust is our commitment to live an authentic life, with sincerity and honesty in all endeavors
  • Integrity is our commitment to the highest ethical standards, to lead with principles and to expect the very best from our employees and our company

These attributes guide every decision and action we make as individuals, and collectively, as Catalyst Pharmaceuticals.

Our work

Catalyst has launched amifampridine, the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS), it’s the first product approved by the FDA for LEMS in more than 35 years.
 
For that approval, Catalyst successfully completed 2 phase 3, multicentered clinical trials of amifampridine in patients with LEMS. 

Patients and Biopharma: Trusted Partners in Fighting Rare Diseases
– Patrick J. McEnany